Ignite Creation Date:
2025-12-24 @ 11:45 AM
Ignite Modification Date:
2025-12-30 @ 10:20 AM
Study NCT ID:
NCT06394661
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-23
First Post:
2024-04-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Sponsor:
Henan Cancer Hospital
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
HELEN-018
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None